DOCSLIB.ORG

Ovarian Cancer Integrative Oncology: Principles, Practice and Outcomes Leanna J

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ovarian Cancer Integrative Oncology: Principles, Practice and Outcomes Leanna J Innovations in Gynecologic Cancer Care 5/12/2017 Ovarian cancer integrative oncology: Principles, Practice and Outcomes Leanna J. Standish ND, PhD, MSAOM, FABNO Bastyr University Research Institute UW School of Medicine, Radiology May 12, 2017 Swedish Hospital lecture 1 Innovations in Gynecologic Cancer Care 5/12/2017 Integrative oncology is a new emerging medical discipline with: • Textbooks • Journals • International society • Board certification • Federal funding • NCI • NCCAM NCCIH 2 2 Innovations in Gynecologic Cancer Care 5/12/2017 Professional societies and board certification Board Certification in naturopathic oncology 2004 FABNO 3 3 Innovations in Gynecologic Cancer Care 5/12/2017 Basic philosophy of integrative oncology is that modalities such as acupuncture, nutrition, psychological counseling, some specific botanical and fungal ‘supplements’ can improve QOL. Basic philosophy of naturopathic oncology is that 1) the natural world and its medicine, both known and unknown, is able to provide safe and effective treatments for cancer patients to improve high quality survival; 2) cancer is also a mind‐body problem and requires psychological interventions. Goals of advanced IO in ovarian cancer includes improve chemo sensitivity, decrease dose‐limiting toxicities of chemotherapy, reduce risk of recurrence after primary cancer treatment, palliation of symptoms and improving quality of death & dying. 4 Innovations in Gynecologic Cancer Care 5/12/2017 Most of our best chemotherapy drugs originated from plants Plant Chemotherapy derivative Pacific Yew (Taxus brevifolia) paclitaxel, docetaxel, albumin‐bound paclitaxel Pink & Red Periwinkle (Catharanthus vincristine and vinblastine, vinorelbine roseus) Chinese “Happy Tree” (Camptotheca camptothecin acuminata) Mayapple (Podophyllum peltatum) teniposide and etoposide 5 5 Innovations in Gynecologic Cancer Care 5/12/2017 Curcumin NFKappaB inhibitor Increase P53 expression Green tea MTOR (serine/threonine kinase) inhibitor; P21 upreg Apoptosis by free radical MOA Bromelain cysteine proteinases with antimetastatic, antithrombotic antiedematous, fibrolytic, Quercetin histone deacetylase inhibitor Tyrosine kinase inhibitor Artemisinin Iron oxidative stress Ascorbate Oxidative burst in malignant cells Melatonin Proteosome inhibitor Anti-estrogen Trametes versicolor (Lu and Disis UW TVG Immune modulator via 2011-2012) Toll-like 2 receptor agonist Dectin-1 agonist Inflammasome agonist 6 6 Innovations in Gynecologic Cancer Care 5/12/2017 Molecular targets in ovarian cancer • EGFR • VEGF • PD‐L1 • MTOR • STAT‐3 • AMPK • Glucose metabolism 7 7 Innovations in Gynecologic Cancer Care 5/12/2017 Evidence to support core therapies in ovarian cancer • Pro‐oxidant cytotoxic single agent therapies • Botanical • Fungal • Hormones • Antioxidants • FDA approved drugs off label • Psychoneuroimmunologic 8 8 Innovations in Gynecologic Cancer Care 5/12/2017 Pro‐oxidant therapies single molecule therapies High dose parenteral ascorbate 25 – 100 grams/infusion Ma, Y., J. Chapman, et al. (2014). "High‐dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy." Sci Transl Med 6(222): 222ra218. 9 9 Innovations in Gynecologic Cancer Care 5/12/2017 IV Vitamin C therapy in ovarian cancer? Ma et al 2014 In vitro Depleted (ATM)/adenosine monophosphate–activated protein kinase (AMPK) pathway mTOR) inhibition and cytotoxic death in ovarian cancer cells. Animal models Parenteral ascorbate + Taxol/Carboplatin synergistically inhibited ovarian cancer in mouse models 10 10 Innovations in Gynecologic Cancer Care 5/12/2017 IV vitamin C RCT in women with ovarian cancer Reduced chemotherapy-associated toxicity in patients with ovarian cancer Improved PFS? Improved OS? 11 11 Innovations in Gynecologic Cancer Care 5/12/2017 Fig. 4. Reduction of toxicity and better PFS and OS in ovarian cancer patients after adding ascorbate to chemotherapy. Yan Ma et al., Sci Transl Med 2014;6:222ra18 12 Published by AAAS 12 Innovations in Gynecologic Cancer Care 5/12/2017 Botanical therapies used in the treatment of ovarian cancer • Epicatechins from green tea • Curcumin • Mistletoe • Indole‐3‐carbinol from broccoli • Quercetin • Bromelain • Artemisinin 13 13 Innovations in Gynecologic Cancer Care 5/12/2017 Green tea epicatechin 14 14 Innovations in Gynecologic Cancer Care 5/12/2017 From Lise Alschuler ND, FABNO 15 15 Innovations in Gynecologic Cancer Care 5/12/2017 Green tea epicatechin active in ovarian, breast and colon cancer. Trudel, D., D. P. Labbe, et al. (2013). "A two‐stage, single‐ arm, phase II study of EGCG‐enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer." Gynecol Oncol 131(2): 357‐ 361. Trudel, D., D. P. Labbe, et al. (2012). "Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies." Gynecol Oncol 126(3): 491‐498. 16 16 Innovations in Gynecologic Cancer Care 5/12/2017 Curcumin (no copyright) 17 17 Innovations in Gynecologic Cancer Care 5/12/2017 Turmeric, Curcumin Oral bioavailability of curcuminoids is low. IV curcumin is likely necessary for full anti‐cancer effect. Active across many solid tumor types. 18 18 Innovations in Gynecologic Cancer Care 5/12/2017 nuclear factor erythroid 2–related factor 2 (Nrf2) controls anti‐ oxidant response to ROS. 19 19 Innovations in Gynecologic Cancer Care 5/12/2017 Curcumin in vitro data Increases chemo and radiosensitivity (Saydmohammed, Joseph et al. 2010; Yallapu, Maher et al. 2010), STAT‐3 (Pan, Yang et al. 2008) AMPK (He, Wang et al. 2016) (Bondi, Emma et al. 2017) Induces apoptosis (Seo, Kim et al. 2016) Lowers drug resistance (Li, Zhou et al. 2016; Zhang, Liu et al. 2017) Lowers platinum resistance (Terlikowska, Witkowska et al. 2014) 20 20 Innovations in Gynecologic Cancer Care 5/12/2017 The adverse side effects of cancer treatment can often be attenuated with oral curcumin. 21 21 Innovations in Gynecologic Cancer Care 5/12/2017 Mistletoe lectins Widely used in Europe –SQ and IV improves QOL in ovarian cancer patients Mistletoe in vitro and animal data and clinical data (Schumacher, Feldhaus et al. 2000; Piao, Wang et al. 2004) 22 22 Innovations in Gynecologic Cancer Care 5/12/2017 Indole‐3‐carbinol Indole‐3‐carbinol In vitro data showing ovarian cancer sensitization to chemotherapy (Taylor‐Harding, Agadjanian et al. 2012). Vulvar cancer 200 mg bid po clinical trial (Naik et al2006) Naik, R., S. Nixon, et al. (2006). "A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia." Int J Gynecol Cancer 16(2): 786‐790. Taylor‐Harding, B., H. Agadjanian, et al. (2012). "Indole‐3‐carbinol synergistically sensitizes ovarian cancer cells bortezomib treatment." Br J Cancer 106(2): 333‐343. 23 23 Innovations in Gynecologic Cancer Care 5/12/2017 Antioxidants Selenium Selenium supplementation reduces risk of ovarian cancer in African American women (Terry, Qin et al. 2017). We use it in BRCA positive patients Terry, P. D., B. Qin, et al. (2017). "Supplemental Selenium May Decrease Ovarian Cancer Risk in African‐American Women." J Nutr 147(4): 621‐627. 24 24 Innovations in Gynecologic Cancer Care 5/12/2017 Higher fungi Trametes versicolor Trametes versicolor: Over 50 trials in colorectal, a few on breast and lung cancer No clinical trials in ovarian cancer. NKCA predicts PFS in ovarian cancer patients (Garzetti, Cignitti et al. 1993) 25 25 Innovations in Gynecologic Cancer Care 5/12/2017 Turkey Tail: Trametes (Coriolus) versicolor, commonly called Turkey Tail is a small flexible polypore fungus that is an important part of the forest ecology as a recycler of dead and dying trees in forests throughout the world. In Japan, T. versicolor is know as kawaratake and in China, the fungus is called Yun Zhi or “cloud-like fungus” 26 26 Innovations in Gynecologic Cancer Care 5/12/2017 Hailing Lu, MD, PHD 27 27 Innovations in Gynecologic Cancer Care 5/12/2017 Strong PSK pre-clinical and clinical data Complex mechanism of action – activates innate immune system via multiple pathways Phase I trial of PSK or placebo + her2neu peptide vaccine + trastuzumab N=30 UW/Bastyr/NCCAM partnership (Disis/Salazar/Standish) NCT01922921 28 28 Innovations in Gynecologic Cancer Care 5/12/2017 Ferry DR et al Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 1996 Apr;2(4):659-68. 29 29 Innovations in Gynecologic Cancer Care 5/12/2017 Quercetin (3,3',4',5,7‐pentahydroxyflavone) 1.Inhibits the growth of tumor cells 2.Prevents cancer metastasis and suppress cancer cell proliferation in animal models. 3.Inhibits signal transduction targets including tyrosine kinases, protein kinase C, and phosphatidyl inositol‐3 kinase 4.In one patient with ovarian cancer refractory to cisplatin, following two courses of quercetin (IV 420 mg/m2), the CA 125 had fallen from 295 to 55. 5. Can be safely administered by i.v. bolus at a dose injection (Ferry et al. 1996) BUT contraindicated with chemotherapy Li, N., C. Sun, et al. (2014). "Low concentration of quercetin antagonizes the cytotoxic effects of anti‐neoplastic drugs in ovarian cancer." PLoS One 9(7): e100314. 30 30 Innovations in Gynecologic Cancer Care 5/12/2017 Proteolytic enzyme therapy in evidence-based complementary oncology: fact or fiction? Integr Cancer Ther. 2008 Dec;7(4):311-6. Beuth J. • Anti-metastatic • Prevents and treats post-surgical fibrosis, • axillary webbing following
Load more

Recommended publications
  • Eurartesim, INN-Piperaquine & INN-Artenimol
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Eurartesim 160 mg/20 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 160 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 20 mg artenimol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). White oblong biconvex film-coated tablet (dimension 11.5x5.5mm / thickness 4.4mm) with a break-line and marked on one side with the letters “S” and “T”. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Eurartesim is indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adults, adolescents, children and infants 6 months and over and weighing 5 kg or more. Consideration should be given to official guidance on the appropriate use of antimalarial medicinal products, including information on the prevalence of resistance to artenimol/piperaquine in the geographical region where the infection was acquired (see section 4.4). 4.2 Posology and method of administration Posology Eurartesim should be administered over three consecutive days for a total of three doses taken at the same time each day. 2 Dosing should be based on body weight as shown in the table below. Body weight Daily dose (mg) Tablet strength and number of tablets per dose (kg) PQP Artenimol 5 to <7 80 10 ½ x 160 mg / 20 mg tablet 7 to <13 160 20 1 x 160 mg / 20 mg tablet 13 to <24 320 40 1 x 320 mg / 40 mg tablet 24 to <36 640 80 2 x 320 mg / 40 mg tablets 36 to <75 960 120 3 x 320 mg / 40 mg tablets > 75* 1,280 160 4 x 320 mg / 40 mg tablets * see section 5.1 If a patient vomits within 30 minutes of taking Eurartesim, the whole dose should be re-administered; if a patient vomits within 30-60 minutes, half the dose should be re-administered.
    [Show full text]
  • Taking Artemisinin to Clinical Anticancer Applications: Design, Synthesis and Characterization
    Taking Artemisinin to Clinical Anticancer Applications: Design, Synthesis and Characterization of pH-responsive Artemisinin Dimer Derivatives in Lipid Nanoparticles Yitong Zhang A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2015 Reading Committee: Tomikazu Sasaki, Chair Rodney J.Y. Ho Champak Chatterjee Program Authorized to Offer Degree: Chemistry i ©Copyright 2015 Yitong Zhang ii University of Washington Abstract Taking Artemisinin to Clinical Anticancer Applications: Design, Synthesis and Characterization of pH-responsive Artemisinin Dimer Derivatives in Lipid Nanoparticles Yitong Zhang Chair of the Supervisory Committee: Professor Tomikazu Sasaki Chemistry iii Abstract Qinghaosu or Artemisinin is an active sesquiterpene lactone isolated from Artemisia annua L. The natural product and its derivatives are known as a first line treatment for malaria. Investigations have also reported that the compound exhibits anti-cancer activities both on cell lines and in animal models. The remarkably stable endoperoxide bridge under ambient conditions is believed to be responsible for the selectivity as well as potency against cells that are rich in iron content. Dimeric derivatives where two artemisinin units are covalently bonded through lactone carbon (C10) show superior efficacies against both malaria parasites and cancer cells. Artemisinin dimer succinate derivative demonstrates a 100-fold enhancement in potency, compared to the natural product, with IC50 values in the low micromolar range. This work focuses on the development of artemisinin dimer derivatives to facilitate their clinical development. Novel pH-responsive artemisinin dimers were synthesized to enhance the aqueous solubility of the pharmacophore motif. Compounds with promising potency against human breast cancer cell lines were selected for lipid and protein based nanoparticle formulations for delivery of the derivatives without the need of organic co-solvents into animal models.
    [Show full text]
  • Despite Improvements, COVID-19'S Health Care Disruptions Persist
    News & Analysis Global Health More Comprehensive Care Drug-Resistant Malaria Detected for Miscarriage Needed Worldwide in Africa Will Require Monitoring About 1 in 10 women will have a miscar- Evidence in Africa that the malaria parasite riage over a lifetime—a statistic that repre- Plasmodium falciparum has developed sents 23 million pregnancies lost annually, genetic variants that confer partial resis- or 44 per minute worldwide, according to tance to the antimalarial drug artemisinin is a series of articles in The Lancet. Despite a warning of potential treatment failure on the magnitude, the articles described mis- the horizon, a drug-resistance monitoring carriage as a misunderstood phenomenon study suggested. and called for more comprehensive care to Partial resistance to artemisinin, the cur- prevent and treat miscarriage. rent frontline treatment for malaria, first The 15% of pregnancies that end in a emerged in Cambodia in 2008 and has be- miscarriage can be attributed to risk fac- come common in Southeast Asia, the au- tors including age during pregnancy, smok- thors wrote. Artemisinin is a fast-acting drug ing, stress, air pollution, and exposure to that typically clears the parasite within 3 pesticides, 1 of the studies reported. For days. It’s usually combined with a longer- Miscarriage is a misunderstood phenomenon, repeated miscarriages, which affect about acting drug to kill any remaining parasites. according to a recent series of articles. 2% of women, another study indicated When artemisinin resistance emerged in that progesterone could increase live-birth Asia, resistance to the combination therapy rates and that levothyroxine may decrease soon followed. 2020 when half of essential services had the risk of miscarriage for women with The current study was part of routine been interrupted.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Impact of Retreatment with an Artemisinin-Based Combination On
    Muhindo Mavoko et al. Trials 2013, 14:307 http://www.trialsjournal.com/content/14/1/307 TRIALS STUDY PROTOCOL Open Access Impact of retreatment with an artemisinin-based combination on malaria incidence and its potential selection of resistant strains: study protocol for a randomized controlled clinical trial Hypolite Muhindo Mavoko1*, Carolyn Nabasumba2, Halidou Tinto3, Umberto D’Alessandro4,5, Martin Peter Grobusch6, Pascal Lutumba1 and Jean-Pierre Van Geertruyden7 Abstract Background: Artemisinin-based combination therapy is currently recommended by the World Health Organization as first-line treatment of uncomplicated malaria. Recommendations were adapted in 2010 regarding rescue treatment in case of treatment failure. Instead of quinine monotherapy, it should be combined with an antibiotic with antimalarial properties; alternatively, another artemisinin-based combination therapy may be used. However, for informing these policy changes, no clear evidence is yet available. The need to provide the policy makers with hard data on the appropriate rescue therapy is obvious. We hypothesize that the efficacy of the same artemisinin- based combination therapy used as rescue treatment is as efficacious as quinine + clindamycin or an alternative artemisinin-based combination therapy, without the risk of selecting drug resistant strains. Design: We embed a randomized, open label, three-arm clinical trial in a longitudinal cohort design following up children with uncomplicated malaria until they are malaria parasite free for 4 weeks. The study is conducted in both the Democratic Republic of Congo and Uganda and performed in three steps. In the first step, the pre-randomized controlled trial (RCT) phase, children aged 12 to 59 months with uncomplicated malaria are treated with the recommended first-line drug and constitute a cohort that is passively followed up for 42 days.
    [Show full text]
  • Clindamycin Plus Quinine for Treating Uncomplicated Falciparum Malaria: a Systematic Review and Meta-Analysis Charles O Obonyo1* and Elizabeth a Juma1,2
    Obonyo and Juma Malaria Journal 2012, 11:2 http://www.malariajournal.com/content/11/1/2 RESEARCH Open Access Clindamycin plus quinine for treating uncomplicated falciparum malaria: a systematic review and meta-analysis Charles O Obonyo1* and Elizabeth A Juma1,2 Abstract Background: Artemisinin-based combinations are recommended for treatment of uncomplicated falciparum malaria, but are costly and in limited supply. Clindamycin plus quinine is an alternative non-artemisinin-based combination recommended by World Health Organization. The efficacy and safety of clindamycin plus quinine is not known. This systematic review aims to assess the efficacy of clindamycin plus quinine versus other anti-malarial drugs in the treatment of uncomplicated falciparum malaria. Methods: All randomized controlled trials comparing clindamycin plus quinine with other anti-malarial drugs in treating uncomplicated malaria were included in this systematic review. Databases searched included: Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and LILACS. Two authors independently assessed study eligibility, extracted data and assessed methodological quality. The primary outcome measure was treatment failure by day 28. Dichotomous data was compared using risk ratio (RR), in a fixed effects model. Results: Seven trials with 929 participants were included. Clindamycin plus quinine significantly reduced the risk of day 28 treatment failure compared with quinine (RR 0.14 [95% CI 0.07 to 0.29]), quinine plus sulphadoxine- pyrimethamine (RR 0.17 [95% CI 0.06 to 0.44]), amodiaquine (RR 0.11 [95% CI 0.04 to 0.27]), or chloroquine (RR 0.11 [95% CI 0.04 to 0.29]), but had similar efficacy compared with quinine plus tetracycline (RR 0.33 [95% CI 0.01 to 8.04]), quinine plus doxycycline (RR 1.00 [95% CI 0.21 to 4.66]), artesunate plus clindamycin (RR 0.57 [95% CI 0.26 to 1.24]), or chloroquine plus clindamycin (RR 0.38 [95% CI 0.13 to 1.10]).
    [Show full text]
  • Phytochemical Regulation of Tumor Suppressive Microrna in Human Breast Cancer Cells
    Phytochemical Regulation of Tumor Suppressive MicroRNA in Human Breast Cancer Cells by Kristina G. H. Hargraves A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Endocrinology in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Gary L. Firestone, Chair Professor G. Steven Martin Professor Jen-Chywan Wang Fall 2013 Phytochemical Regulation of Tumor Suppressive MicroRNA in Human Breast Cancer Cells © 2013 By Kristina G. H. Hargraves ABSTRACT Phytochemical Regulation of Tumor Suppressive MicroRNA in Human Breast Cancer Cells by Kristina G. H. Hargraves Doctor of Philosophy in Endocrinology University of California, Berkeley Professor Gary L. Firestone, Chair MicroRNA post-transcriptionally regulate more than half of the transcribed human genome and could be potential targets of anti-cancer therapeutics. The microRNA family, miR- 34, is a component of the p53 tumor suppressor pathway and has been shown to mediate induction of cell cycle arrest, senescence, and apoptosis in cancer cells. Indole-3-carbinol (I3C) derived from cruciferous vegetables, artemisinin isolated from the sweet wormwood plant and artesunate derived from the carbonyl reduction of artemisinin effect components of the p53 pathway to growth arrest human cancer cells, implicating a potential role for miR-34a in their anti-proliferative effects. Flow cytometry and Taqman semi-quantitative PCR analysis of I3C, artemisinin and artesunate treated human breast cancer cells indicate all three phytochemicals upregulate miR- 34a in a dose and time-dependant manner that correlates with a pronounced G1 cell cycle arrest. Western blot analysis revealed miR-34a upregulation correlates with induction of functional p53 by I3C as well as artesunate and artemisinin mediated decreases in estrogen-receptor alpha (ERα) and the cyclin-dependant kinase CDK4, a known target of miR-34a inhibition.
    [Show full text]
  • Bulk Drug Substances Under Evaluation for Section 503A
    Updated July 1, 2020 Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act Includes three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Concerns • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Section 503A Categories • Removal from category 3 o Artesunate – This bulk drug substance is a component of an FDA-approved drug product (NDA 213036) and compounded drug products containing this substance may be eligible for the exemptions under section 503A of the FD&C Act pursuant to section 503A(b)(1)(A)(i)(II). This change will be effective immediately and will not have a waiting period. For more information, please see the Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A and the final rule on bulk drug substances that can be used for compounding under section 503A, which became effective on March 21, 2019. 1 Updated July 1, 2020 503A Category 1 – Bulk Drug Substances Under Evaluation • 7 Keto Dehydroepiandrosterone • Glycyrrhizin • Acetyl L Carnitine/Acetyl-L- carnitine • Kojic Acid Hydrochloride • L-Citrulline • Alanyl-L-Glutamine • Melatonin • Aloe Vera/ Aloe Vera 200:1 Freeze Dried • Methylcobalamin • Alpha Lipoic Acid • Methylsulfonylmethane (MSM) • Artemisia/Artemisinin • Nettle leaf (Urtica dioica subsp. dioica leaf) • Astragalus Extract 10:1 • Nicotinamide Adenine Dinucleotide (NAD) • Boswellia • Nicotinamide
    [Show full text]
  • Drugs Affectin the Autonomic Nervous System
    Fundamentals of Medical Pharmacology Paterson Public Schools Written by Néstor Collazo, Ph.D. Jonathan Hodges, M.D. Tatiana Mikhaelovsky, M.D. for Health and Related Professions (H.A.R.P.) Academy March 2007 Course Description This fourth year course is designed to give students in the Health and Related Professions (H.A.R.P.) Academy a general and coherent explanation of the science of pharmacology in terms of its basic concepts and principles. Students will learn the properties and interactions between chemical agents (drugs) and living organisms for the rational and safe use of drugs in the control, prevention, and therapy of human disease. The emphasis will be on the fundamental concepts as they apply to the actions of most prototype drugs. In order to exemplify important underlying principles, many of the agents in current use will be singled out for fuller discussion. The course will include the following topics: ¾ The History of Pharmacology ¾ Terminology Used in Pharmacology ¾ Drug Action on Living Organisms ¾ Principles of Pharmacokinetics ¾ Dose-Response Relationships ¾ Time-Response Relationships ¾ Human Variability: Factors that will modify effects of drugs on individuals ¾ Effects of Drugs Attributable to Varying Modes of Administration ¾ Drug Toxicity ¾ Pharmacologic Aspects of Drug Abuse and Drug Dependence Pre-requisites Students must have completed successfully the following courses: Biology, Chemistry, Anatomy and Physiology, Algebra I and II Credits: 5 credits Basic Principles of Drug Action Introduction to Pharmacology a. Basic Mechanisms of Drug Actions b. Dose-response relationships c. Drug absorption d. Biotransformation of Drugs e. Pharmacokinetics f. Factors Affecting Drug Distribution g. Drug Allergy and Pharmacogenetics h.
    [Show full text]
  • Dihydroartemisinin and Gefitinib Synergistically Inhibit NSCLC Cell Growth and Promote Apoptosis Via the Akt/Mtor/STAT3 Pathway
    MOLECULAR MEDICINE REPORTS 16: 3475-3481, 2017 Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway HONG JIN1, AI-YING JIANG2, HAN WANG3, YONG CAO4, YAN WU5 and XIAO-FENG JIANG1 1Department of Clinical Laboratory, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001; 2Department of Pneumology, Hongqi Hospital; Departments of 3Clinical Skills Center, 4Pathology and 5Medical Research Center, Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China Received March 9, 2016; Accepted February 20, 2017 DOI: 10.3892/mmr.2017.6989 Abstract. Non-small cell lung cancer (NSCLC) is among the expression of Bcl-2-associated X protein. In conclusion, leading causes of cancer-associated mortality worldwide. In the present results suggested that the combination of DHA clinical practice, therapeutic strategies based on drug combi- and gefitinib may have potential as a novel and more effec- nations are often used for the treatment of various types of tive therapeutic strategy for the treatment of patients with cancer. The present study aimed to investigate the effects of NSCLC. the combination of dihydroartemisinin (DHA) and gefitinib on NSCLC. Cell Counting kit 8 assay was used to evaluate Introduction cell viability. Transwell assays were performed to investigate cellular migration and invasion, and cellular apoptosis was According to GLOBOCAN, lung cancer is among the most evaluated using the terminal deoxynucleotidyl transferase common types of cancer worldwide (1). Non-small cell lung dUTP nick-end labeling assay. Flow cytometry was used to cancer (NSCLC) comprises 85% of all types of lung cancer. investigate cell cycle distribution and the expression levels of NSCLC is relatively insensitive to chemotherapy compared target proteins were determined using western blot analysis.
    [Show full text]
  • Artemisia Annua L
    WHO Position Statement (June 2012) Effectiveness of Non-Pharmaceutical Forms of Artemisia annua L. against malaria ___________________________________________________________________________ The World Health Organization (WHO) recommends artemisinin-based combination therapy (ACT) for the treatment of uncomplicated malaria due to Plasmodium falciparum (P. falciparum). ACTs recommended by WHO combine an artemisinin derivative such as artemether, artesunate or dihydroartemisinin with an effective antimalarial medicine. The five currently recommended ACTs are listed in the WHO guidelines for the treatment of malaria, 2010 (1). A number of herbal remedies made of Artemisia annua L. (A. annua) dry leaves are suggested for the treatment and prevention of malaria. However, WHO does not recommend the use A. annua plant material ,in any form, including tea, for the treatment or the prevention of malaria. The WHO recommendation is based on the review of scientific findings. Firstly, the content of artemisinin in the leaves is influenced by many genetic, agricultural and environmental factors (2-4). Total recovery of artemisinin can vary from 0.01 to 1.4% weight% of dry leaf mass (4-5). Harvesting season, drying procedures and storage conditions also influence the content in artemisinin (6-8). A. annua leaves stored at temperatures above 20°C with high relative humidity cause a substantial loss of artemisinin content (6), which makes it imperative to store the leaves in cool and dry conditions. Crushing the leaves before storage can also affect the artemisinin content (6). People living in rural areas may not have adequate storage facilities in their homes to ensure that the content of artemisinin is fully maintained over long periods of time.
    [Show full text]